The use of bisphosphonates in elderly cancer patients

Oncologist

Volumn 12, Issue 1, 2007, Pages 62-71

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Bone metastases; Clodronate; Elderly; Ibandronate; Pamidronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; LORON; PAMIDRONIC ACID; PLACEBO; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; JAW DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGED; AGED, 80 AND OVER; DIPHOSPHONATES; FEMALE; HUMANS; MALE; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 33846448782     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-1-62     Document Type: Review

References (62)

1. Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664.
3. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
4. Coleman RE. Bisphosphonates: Clinical experience. The Oncologist 2004;9(suppl 4):14-27.
5. Clemons M, Dranitsaris G, Cole D et al. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. The Oncologist 2006;11:227-233.
6. Paterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
7. Lahtinen R, Laakso M, Palva I et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992;340:1049-1052.
8. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: A randomized study. J Intern Med 1999;246:67-74.
9. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [in French]. Bull Cancer 2001;88:701-707.
10. Jagdev SP, Purohit P, Heatley S et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-1438.
11. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-2044.
12. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854.
13. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-493.
14. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myleoma Aredia Study Group. J Clin Oncol 1998;16:593-602.
15. Small EJ, Smith MR, Seaman JJ et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-4284.
16. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
17. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
18. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
19. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882.
20. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-3157.
21. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
22. Fulfaro F, Arcara C, Badalamenti G et al. The use of zoledronic acid in the treatment of painful bone metastases from prostate cancer. Proc Am Soc Clin Oncol 2003;22:428a.
23. Vogel CL, Yanagihara RH, Wood AJ et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. The Oncologist 2004;9:687-695.
24. Wardley A, Davidson N, Barrett-Lee P et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869-1876.
25. Body JJ, Kanis J, Diel I et al. Risk reductions in metastatic breast cancer: Multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc Am Soc Clin Oncol 2003;22:46a.
26. Body JJ, Diel IJ, Bell R et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-312.
27. Tripathy D, Budde M. Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: A methodological comparison. Bone 2004;34(suppl 1):S91.
28. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
29. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-1137.
30. Body JJ, Lichinitser M, Tjulandin S et al. Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Comparative bone turnover marker and safety data. Bone 2006;38(suppl 1):69a
31. Barrett-Lee P, Murray N. Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: The NCRI ZICE trial. Bone 2006;38(suppl 1):67a.
32. Rivkin S. Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: The SWOG trial. Bone 2006;38(suppl 1):82a.
33. Diel IJ, Body JJ, Lichinitser MR et al. Improved quality of life after longterm treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704-1712.
34. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-235.
35. Heidenreich A, Ohlmann C, Olbert P et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):S270.
36. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: A pilot study. J Clin Oncol 2004;22:3587-3592.
37. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005 Jul 20;(3):CD003474.
38. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
39. Goldschmidt H, Lannert H, Bommer J et al. Multiple myeloma and renal failure. Nephrol Dial Transplant 2000;15:301-304.
40. Haleblian GE, Skinner EC, Dickinson MG et al. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol 1998;160:2011-2014.
41. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol 1992;19:521-528.
42. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406.
43. Atula S, Powles T, Paterson A et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003;26:661-671.
44. Tralongo P, Repetto L, Di Mari A et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004;67:112-116.
45. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
46. Antràs L, Smith M, Neary M et al. Comparison of renal impairment in multiple myeloma patients treated with zoledronic acid or ibandronate: A retrospective medical records review. Bone 2006;38(suppl 1):87a.
47. Novartis Pharmaceuticals Corporation. Zometa® (zoledronic acid). US summary of product characteristics. East Hanover, NJ: Novartis Pharmaceuticals Corporation, November 2004.
48. Novartis International AG. Zometa® (zoledronic acid). EU summary of product characteristics. Basel, Switzerland: Novartis International AG, May 2005.
49. Body JJ, Diel IJ, Tripathy D et al. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results. Eur J Cancer Care 2006;15:299-302.
50. Pecherstorfer M, Rivkin S, Body JJ et al. Long-term safety of intravenous ibandronate for up to 4 years in metastatic breast cancer: An open-label trial. Clin Drug Invest 2006;26:315-322.
51. Heidenreich A, Ohlmann C, Bergner R. Renal safety of loading dose ibandronate in urologic patients with compensated renal insufficiency. Cancer Treat Rev 2005;31(suppl 1):S50.
52. Menssen HD, Sakalova A, Fontana A et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-2359.
53. Henrich D, Bergner R, Hoffmann M et al. Ibandronate in the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure. Support Care Cancer 2005;13:463;21a-150a.
54. Henrich D, Bergner R, Hoffman M et al. Renal safety of ibandronate in elderly myeloma patients with pre-existing renal deterioration. Paper presented at: Sixth Conference of the International Society for Geriatric Oncology; September 29-October 1, 2005; Geneva.
55. Bergström B, Lichinitser M, Body JJ. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: Evidence from comparative phase II/III trials. Bone 2006;38(suppl 1):68a-69a.
56. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging complication of supportive cancer therapy. Cancer 2005;104:83-93.
57. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
58. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24:945-952.
59. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study. J Clin Oncol 1995;13:2427-2430.
60. McLachlan S-A, Cameron D, Murray R et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: Long-term follow-up experience. Clin Drug Invest 2006;26:43-48.
61. Fulfaro F, Casuccio A, Ticozzi C et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998;78:157-169.
62. Janjan N. Bone metastases: Approaches to management. Semin Oncol 2001;28:28-34.